

# LC/MS/MS Analysis of Drugs of Abuse using Biocompatible Solid Phase Microextraction (BioSPME)



Sara Smith, Emily Barrey, Craig Aurand, Dave Bell, and Candace Price  
MilliporeSigma, Bellefonte, PA, USA

## Introduction

The field of illicit drug testing has recently become a constantly changing environment with the rapid development of unregulated designer and synthetic compounds. These compounds are reported to generate stimulating effects similar to that of methamphetamine, heroin and MDMA. The difficulty for forensic testing facilities is the fact that these compounds are not detected under normal ELISA testing methods; therefore, more specific LC/MS based approaches are necessary. This study demonstrates the benefits of Biocompatible Solid Phase Microextraction (BioSPME) over traditional "dilute and shoot" and protein precipitation methods for the enrichment of illicit drugs and drugs of abuse directly from biological matrices. The utility and unique selectivity of these sampling devices will also be explored.

## BioSPME Theory

- BioSPME is an equilibrium extraction technique in which the analyte of interest partitions between the sample matrix and the coating of a BioSPME fiber.
- For this specific application, the coating consists of C18 functionalized silica particles that are embedded within a proprietary biocompatible binder.
- The purpose of the binder is to reduce or eliminate extraction of matrix interferences, without reducing analyte extraction. Therefore, this methodology allows for isolation of target analytes, while minimizing the presence of matrix, resulting in a highly sensitive microsampling technique.

Figure 1. Schematic of a BioSPME Fiber Extraction





Figure 2. BioSPME LC Tip Format



## Analytes of Interest

- Model Set 1-Cathinones in Urine:** Naphyrone,  $\alpha$ -Pyrrolidinovalerophenone ( $\alpha$ -PVP), 3,4-methylenedioxypropylvalerone (MDPV), butylone, methylone.
- Model Set 2-Drugs of Abuse in Urine and Plasma:** Cocaine, cocaethylene, benzoyllecgonine, methadone, 2-Ethyl-1,5-dimethyl-3,3-diphenylpyrrolinium (EDDP), norfentanyl.




The life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada.

Ascentis is a registered trademark of Sigma-Aldrich Co. LLC. Agilent is a registered trademark of Agilent Technologies, Inc. MilliporeSigma and the M logo are trademarks of Merck KGaA, Darmstadt, Germany.


© 2016 EMD Millipore Corporation, Billerica, MA USA. All rights reserved. Lit. No. T416076

## Methods

### Cathinones: Procedure




### Drugs of Abuse: Procedure



## Results

### Linearity



## Results (contd.)


### Sensitivity

These comparisons are made for the analysis of benzoyllecgonine from plasma. The BioSPME method allowed for a 2X pre-concentration, resulting in a greater increase in sensitivity

| Technique             | Calculated Limit of Detection (ng/mL) | Calculated Limit of Quantitation (ng/mL) |
|-----------------------|---------------------------------------|--|
| BioSPME               | 45.4                                  | 151                                      |
| Protein Precipitation | 176                                   | 585                                      |

### Analyte Response


TIC for Drugs of Abuse from Post Extraction Urine Spike



The background for the "dilute and shoot" sample significantly suppressed any analyte signal.


### Phospholipid Monitoring

Comparison of Phospholipid Response from Plasma Samples




### Matrix Factors and %RSD's - Urine

| Analyte          | Matrix Factor Range BioSPME | Matrix Factor Range Dilution |
|------------------|-----------------------------|------------------------------|
| Naphyrone        | 1.11-1.15                   | 0.38-1.23                    |
| $\alpha$ -PVP    | 1.11-1.16                   | 0.58-1.62                    |
| MDPV             | 1.14-1.12                   | 1.02-1.88                    |
| Butylone         | 1.08-1.15                   | 0.75-1.46                    |
| Methylone        | 1.16-1.23                   | 0.21-1.08                    |
| Cocaine          | 0.84-1.23                   | 0.71-1.47                    |
| Cocaethylene     | 0.86-1.32                   | 0.74-1.57                    |
| Benzoyllecgonine | 0.86-1.33                   | 0.48-1.38                    |
| Methadone        | 0.86-1.35                   | 0.57-1.48                    |
| EDDP             | 0.91-1.42                   | 0.84-1.91                    |
| Norfentanyl      | 0.81-1.40                   | 0.68-1.67                    |



### Matrix Factors and %RSD's - Plasma

| Analyte          | Matrix Factor Range BioSPME | Matrix Factor Range Protein Precipitation |
|------------------|-----------------------------|---|
| Cocaine          | 1.03-1.06                   | 0.71-1.47                                 |
| Cocaethylene     | 1.08-1.37                   | 0.74-1.57                                 |
| Benzoyllecgonine | 1.10-1.70                   | 0.48-1.38                                 |
| Methadone        | 1.03-1.39                   | 0.57-1.48                                 |
| EDDP             | 1.13-1.43                   | 0.84-1.91                                 |



Significant variation was observed in the matrix factors (range and %RSD) for the protein precipitated plasma samples.

## Conclusions

- In conclusion, BioSPME was determined to be superior to more traditional biological sample preparation techniques such as "dilute and shoot" and protein precipitation.
- In terms of quantitative analysis parameters, BioSPME resulted in a broader dynamic range, improved linearity, and increased sensitivity.
- Due to the ability of the proprietary biocompatible binder to greatly reduce co-extraction of biological interferences, matrix effects were found to be less significant. Matrix effects were also found to be more consistent across samples. The benefit of matrix removal was especially evident when working with biological matrices containing a large concentration of phospholipids, such as plasma.
- Finally, BioSPME allowed for acceptable recoveries of all 11 analytes tested. For many analytes tested, this technique was found to have greater precision than the traditional methodologies.